Japan Medical Device Approval Pmda Approval Service

Scope and evidence must be confirmed before any paid tests or filings.

Japan medical device approval is an execution project, not a single PMDA certificate. Before drafting an application, determine the device’s Japanese classification and whether a designated certification standard covers its intended use. Then establish the eligible applicant and manufacturing-site registrations, assemble controlled evidence, submit to the correct body, answer review questions and maintain the authorized product. The workflow below distinguishes MHLW approval, third-party certification and PMDA notification; the route for a specific product must be confirmed from its JMDN classification and claims.

Select the legal route before preparing forms

The PMD Act distinguishes risk classes I–IV. For Class II and eligible Class III products, existence and applicability of a designated certification standard is decisive. PMDA reviews applications for MHLW approval; a registered certification body (RCB) assesses qualifying certification applications. A filing cannot be routed solely by an EU or US device class.

Japanese category	Submission or assessment	Result and decision-maker
Class I	Product notification to PMDA; no PMDA scientific product review.	A notification is not an MHLW marketing approval. The notifying party remains responsible for conformity.
Class II or designated Class III, where an applicable certification standard exists	Certification application to a registered certification body (RCB).	RCB certification if the product, claims and applicable standards meet the defined scope.
Other Class II or Class III	Marketing approval application examined by PMDA.	MHLW approval following the applicable product review and QMS steps.
Class IV	Marketing approval application examined by PMDA.	MHLW approval; no automatic substitution with overseas clearance.

A device’s JMDN code, intended purpose, risk class and any applicable designated standard must be recorded as the route decision. Ask for regulatory clarification where the boundaries remain uncertain; do not file a certification application merely because the device is Class II.

Confirm who applies, who manufactures and who communicates

A Japanese marketing authorization holder (MAH), or another eligible applicant/designated arrangement under the particular route, is central to market entry. Relevant foreign manufacturing sites require separate registration. PMDA explains that the foreign manufacturer is the applicant for foreign-manufacturer registration even when a Japanese proxy handles that filing. Document the arrangements before an authority submission.

Party	Owns or supplies	Filing handoff
Device manufacturer	Design history, complete manufacturing-site map, testing, clinical rationale, quality evidence and technical answers.	Approves final specifications and supplies traceable originals; identifies registered sites where applicable.
Japanese MAH / designated local party	Checks eligibility, licensing, Japanese filing data, coordination, post-market safety and authority correspondence according to its legal role.	Confirms the correct applicant, signs/submits where empowered and tracks correspondence and duties.
PMDA / MHLW / RCB	PMDA: review and related inspections; MHLW: approval decision; RCB: certification for eligible devices.	Use the body dictated by the confirmed route, not whichever appears faster.

For a foreign manufacturing-site registration, first obtain the required business codes for the foreign company and each relevant site. PMDA states that the foreign manufacturer is the applicant, but the registration filing must be handled through the Japanese marketing authorization holder or other permitted Japanese intermediary; the foreign manufacturer cannot submit it directly. A business code is not itself a site registration.

Release the dossier only after four evidence gates

No universal document package fits every Japanese device. Approval dossiers may follow new, improved or generic device categories. Structure the application around the specific classification, Japanese claims, reviewer requirements and evidence gaps; keep its contents consistent with any QMS inspection submission.

Controlled package	Minimum release check
Product identity and proposed claims	JMDN rationale, model and variant scope, intended purpose, design description, indications, contraindications and draft Japanese labeling must agree.
Safety and performance evidence	Risk management, verification/validation, applicable standards, nonclinical test reports and clinical justification or data where required; retain underlying source records.
Manufacturing and quality evidence	Site/activity list, required foreign site registrations, Japan QMS conformity approach under Ordinance 169 and current QMS inspection/certification evidence.
Application administration and vigilance	Applicant authority, Japanese forms and attachments, controlled translations, fees where prescribed, query-response owner and post-market reporting interface.

An ISO 13485 certificate, MDSAP report, CE marking or FDA clearance may contribute evidence but does not by itself establish Japanese product authorization. PMDA confirms that accepted MDSAP reports can support Japanese QMS assessment under its rules, not replace a product filing.

Six-stage Japan PMDA/RCB filing and review workflow

Freeze the Japanese product definition: indications, variants, JMDN, class and whether a named certification standard actually applies.
Validate the Japan applicant and licensing arrangement; identify relevant production, sterilization, design and storage activities and confirm required site registrations.
Issue a documented gap list, secure final reports and underlying data, reconcile Japanese claims, technical dossier and QMS scope, and approve a version-controlled release.
Prepare the current Japanese application or notification package, select the correct PMDA or RCB route, and confirm the permitted submission channel and applicable fees.
Submit through the authorized party, archive acknowledgment, answer technical deficiencies consistently, manage QMS or data-integrity checks where applicable, and log amendments.
Verify the actual approval, certification or notification status and scope before release; hand the final file, labeling, change control and vigilance duties to the MAH.

PMDA has published FD/DWAP and online-gateway submission guidance, including a July 2026 update. Check the particular form and current electronic submission eligibility: an electronic upload or receipt alone is not proof of product approval.

Submission-channel control: PMDA states that FD or DWAP can prepare device notification data; with the ordinary DWAP route, sending electronic data does not remove the requirement to deliver printed notification forms. A separate eligible fully online submission route may dispense with paper. PMDA does not accept device notifications by email. Verify the exact form, channel and proof of receipt for this filing; the July 2026 online-submission notice is not a blanket waiver of paper documents.

Common delay triggers and practical corrections

Wrong route: a Class II product is sent to an RCB without checking that its designated standard covers the intended use. Correct by documenting the JMDN, standard and product/claim fit before paying or filing.
Applicant or site mismatch: the dossier names an unconfirmed holder or omits a manufacturing operation requiring registration. Correct by reconciling license, proxy authority and site/activity inventory.
Evidence discontinuity: Japanese labeling, test reports and risk documentation describe different models or indications, or underlying data cannot be produced. Correct with a controlled claims-and-evidence matrix and source record review.
Review-response drift: manufacturer and Japan applicant answer separately, creating contradictory commitments. Correct with one question log, a named accountable reviewer, response deadlines set by the authority and change-controlled submissions.

Maintain the Japanese approval, certification or notification after filing

Approval, certification and notification are different legal outcomes. Confirm the exact product scope and any conditions before commercial distribution. The responsible Japanese party must operate the relevant post-market safety and reporting processes; product complaints, field actions, labeling changes, manufacturing changes and new indications require documented regulatory impact screening. A significant change may require a new or supplemental regulatory step: do not assume the original authorization covers it. Keep the controlled dossier, QMS records and authority correspondence available for inspection and updates.

What an approval-filing engagement should deliver

An execution mandate should specify deliverables and responsible signatories rather than promise PMDA approval. The scope is confirmed against the device and its route; scientific testing, QMS remediation, Japanese holder arrangements and official fees should be separately defined when needed.

Signed-off route memorandum identifying class, JMDN, standard applicability and competent recipient.
Applicant, foreign-site and responsibility register with outstanding authorizations clearly marked.
Japanese filing index, controlled technical evidence map, deficiency tracker and submission-ready documents.
Authority-submission record, questions/answers ledger and post-decision handover/change-control checklist.

Where this page stops

This page owns approval-filing execution: evidence, applicant, regulator review and maintenance. Long-range regulatory strategy and broad market-entry comparisons are separate tasks; a narrower step-by-step registration intake also has its own page.

Official regulatory sources

Questions before committing to a filing

Does CE marking or FDA clearance authorize our device in Japan?

No. Overseas clearances may inform the evidence package but the Japan route depends on Japanese classification, applicable standards, authorized applicant and the relevant Japan filing outcome.

Our device is Class II: should we send it to a certification body?

Only if the designated certification standard actually covers the device and its proposed claims. Otherwise an MHLW approval route with PMDA review may be required. Verify JMDN and the standard first.

Can a foreign manufacturer apply without any Japanese organization?

Do not assume so. Japanese MAH or designated-party arrangements apply to product market entry. Even where a special foreign approval structure is used, local responsibilities remain; manufacturing-establishment registration has its own applicant/proxy rules.

Must we complete QMS and all clinical tests before submission?

Confirm what the specific application and QMS assessment require. Evidence needed to support claims must be available and consistent; clinical evidence varies by device and approval category. A foreign QMS certificate does not automatically replace Japanese assessment.

Can we change intended use or a manufacturing site after authorization?

Treat a change as a regulatory decision, not a routine document edit. Compare it with the authorized product, assess QMS and safety impacts, and determine with the responsible Japanese party whether an additional approval, certification or notification procedure is required.